PXS25 Phase I trials
to commence
Cash at 30 June of
$125 million
Commercialization
expenditure increases
Aridol supplied to
two new European
countries
Contact Details
Further information on Pharmaxis can be
obtained from www.pharmaxis.com.au
or by contacting David McGarvey,
Chief Financial Officer:
Telephone: +612 9454 7200
david.mcgarvey@pharmaxis.com.au
Pharmaxis Ltd
ABN 75 082 811 630
20 Rodborough Road
Frenchs Forest NSW 2086
Quarterly Report to Shareholders Issue 23
Financial Statement Data Unaudited
(International Financial Reporting Standards)
(000 except per share data)
Income Statement Data
Three months ended Twelve months ended
30-Jun-09 30-Jun-08 30-Jun-09 30-Jun-08
A$ A$ A$ A$
Revenue from sale of goods 141 197 595 527
Cost of sales (35) (36) (153) (129)
Gross profit 106 161 442 398
Interest 763 2,233 5,347 7,402
Other income 246 654 523 1,576
Expenses
Research & development (8,531) (5,995) (29,308) (19,996)
Commercial (1,865) (1,452) (6,202) (4,557)
Administration (1,541) (1,446) (5,800) (5,231)
Finance expenses (122) (122)
Total expenses (12,059) (8,893) (41,432) (29,784)
Loss before income tax (10,944) (5,845) (35,120) (20,408)
Income tax expense (24) (15) (51) (32)
Loss for the period (10,968) (5,860) (35,171) (20,440)
Basic and diluted earnings (loss) per share $ (0.055) (0.030) (0.180) (0.108)
Depreciation & amortisation 475 252 1,265 1,023
Fair value of options issued under employee plan 631 829 2,432 3,433
Balance Sheet Data
As at
30-Jun-09 30-Jun-08
A$ A$
Cash and cash equivalents 124,993 111,842
Property, plant & equipment 32,698 3,668
Intangible assets 1,193 1,227
Total assets 163,997 125,049
Total liabilities (26,306) (5,928)
Net assets 137,691 119,121
Cash Flow Data
Three months ended Twelve months ended
30-Jun-09 30-Jun-08 30-Jun-09 30-Jun-08
A$ A$ A$ A$
Cash flows from operating activities (10,143) (2,179) (26,422) (18,853)
Cash flows from investing activities (1,800) (2,233) (11,542) (5,059)
Cash flows from financing activities 51,104 1 51,115 59,572
Net increase (decrease) in cash held 39,161 (4,411) 13,151 35,660
Share Data
Ordinary Shares as at
30-Jun-09 30-Jun-08
Ordinary shares on issue 217,659 194,515
Options over ordinary shares outstanding 15,075 11,536
|